Literature DB >> 26315830

Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors.

Harun Ilhan1, Anna Goritschan1, Philipp Paprottka2, Tobias F Jakobs3, Wolfgang P Fendler1, Andrei Todica1, Peter Bartenstein1, Marcus Hacker4, Alexander R Haug5.   

Abstract

UNLABELLED: This study analyzed the predictive value of (99m)Tc-labeled macroaggregated albumin ((99m)Tc-MAA) SPECT for (90)Y-labeled resin microsphere therapy (radioembolization) by comparing uptake on pretherapeutic (99m)Tc-MAA SPECT with uptake on posttherapeutic (90)Y-bremsstrahlung SPECT.
METHODS: We included 502 patients (55% male; mean age ± SD, 62 ± 11 y) who underwent radioembolization between 2005 and 2013 because of primary or secondary liver malignancies (colorectal cancer [n = 195, 38.8%], neuroendocrine tumors [n = 77, 15.3%], breast cancer [n = 68, 13.5%], hepatocellular carcinoma [n = 59, 11.8%], cholangiocellular carcinoma [n = 40, 8.0%], or urologic tumors [n = 14, 2.8%]). Manually drawn regions of interest around tumors and adjacent healthy liver tissue for up to 3 lesions per patient on (99m)Tc-MAA and (90)Y-bremsstrahlung scans were used to quantify mean counts per pixel and evaluate the mean tumor-to-background ratio (TBR). Data were given as mean ± SD. Additionally, uptake in lesions on (99m)Tc-MAA and (90)Y-bremsstrahlung scans was graded visually as homogeneously higher than (grade 1), heterogeneously higher than (grade 2), equal to (grade 3), or lower than (grade 4) uptake in normal liver tissue. The Mann-Whitney U test and Spearman correlation were used to evaluate statistically significant differences between (99m)Tc-MAA and (90)Y-bremsstrahlung SPECT.
RESULTS: In total, 1,008 lesions were analyzed. Of the 23% (230/1,008) of lesions that had grade 1 uptake on (99m)Tc-MAA SPECT, 81% (186/230) remained grade 1 after radioembolization whereas 16% (37/230) were grade 2. Of the lesions with grade 2 uptake on (99m)Tc-MAA SPECT, 16% had grade 1 uptake and 82% grade 2 uptake after radioembolization. Of the lesions with grade 3 uptake, however, 27% had grade 1 uptake and 47% grade 2 uptake after radioembolization. Even among the lesions with grade 4 uptake on (99m)Tc-MAA SPECT, 21% had grade 1 uptake and 46% grade 2 uptake after radioembolization. The mean TBR on (99m)Tc-MAA and (90)Y-bremsstrahlung SPECT showed a significant, though low, correlation in the total population (r = 0.26; P < 0.001) and in hepatocellular carcinoma (r = 0.4; P < 0.001), cholangiocellular carcinoma (r = 0.3; P < 0.05), breast cancer (r = 0.3; P < 0.001), colorectal cancer (r = 0.2; P < 0.001), and neuroendocrine tumors (r = 0.2; P < 0.01).
CONCLUSION: Although significant for most lesions, the correlation between (99m)Tc-MAA and (90)Y-microsphere mean TBR was low. Classifying uptake into 4 grades revealed that lesions with high uptake on (99m)Tc-MAA SPECT maintain high uptake within radioembolization. More than 60% of lesions with a pretherapeutically lower uptake than in healthy liver tissue, however, showed high uptake within radioembolization. Patients with low tumor uptake on pretherapeutic (99m)Tc-MAA imaging should not be excluded from radioembolization.
© 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  90Y radioembolization; 99mTc macroaggregated albumin; SIRT; SPECT/CT; liver tumor

Mesh:

Substances:

Year:  2015        PMID: 26315830     DOI: 10.2967/jnumed.115.162685

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  21 in total

Review 1.  Yttrium-90 Radioembolization Dosimetry: What Trainees Need to Know.

Authors:  Alexander Villalobos; Mohamed M Soliman; Bill S Majdalany; David M Schuster; James Galt; Zachary L Bercu; Nima Kokabi
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

Review 2.  Update on novel trends in PET/CT technology and its clinical applications.

Authors:  Stephan Walrand; Michel Hesse; François Jamar
Journal:  Br J Radiol       Date:  2016-11-25       Impact factor: 3.039

3.  Personalized Dosimetry for Liver Cancer Y-90 Radioembolization Using Computational Fluid Dynamics and Monte Carlo Simulation.

Authors:  Emilie Roncali; Amirtahà Taebi; Cameron Foster; Catherine Tram Vu
Journal:  Ann Biomed Eng       Date:  2020-01-31       Impact factor: 3.934

4.  Assessing Spatial Concordance Between Theranostic Pairs Using Phantom and Patient-Specific Acceptance Criteria: Application to 99mTc-MAA SPECT/90Y-Microsphere PET.

Authors:  Justin K Mikell; Bill S Majdalany; Dawn Owen; Kelly C Paradis; Yuni K Dewaraja
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-04-22       Impact factor: 7.038

Review 5.  Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2017-05-02       Impact factor: 3.959

Review 6.  Trans-arterial Radioembolization Dosimetry in 2022.

Authors:  Etienne Garin; Boris Guiu; Julien Edeline; Yan Rolland; Xavier Palard
Journal:  Cardiovasc Intervent Radiol       Date:  2022-08-18       Impact factor: 2.797

Review 7.  Radioembolization of Colorectal Liver Metastases: Indications, Technique, and Outcomes.

Authors:  F Edward Boas; Lisa Bodei; Constantinos T Sofocleous
Journal:  J Nucl Med       Date:  2017-09       Impact factor: 10.057

8.  Selective Internal Radiation Therapy With Yttrium-90 Glass Microspheres: Biases and Uncertainties in Absorbed Dose Calculations Between Clinical Dosimetry Models.

Authors:  Justin K Mikell; Armeen Mahvash; Wendy Siman; Veera Baladandayuthapani; Firas Mourtada; S Cheenu Kappadath
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-07-27       Impact factor: 7.038

9.  High quality imaging and dosimetry for yttrium-90 (90Y) liver radioembolization using a SiPM-based PET/CT scanner.

Authors:  Heying Duan; Mohamed H Khalaf; Valentina Ferri; Lucia Baratto; Shyam M Srinivas; Daniel Y Sze; Andrei Iagaru
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-14       Impact factor: 9.236

10.  International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres.

Authors:  Hugo Levillain; Oreste Bagni; Christophe M Deroose; Arnaud Dieudonné; Silvano Gnesin; Oliver S Grosser; S Cheenu Kappadath; Andrew Kennedy; Nima Kokabi; David M Liu; David C Madoff; Armeen Mahvash; Antonio Martinez de la Cuesta; David C E Ng; Philipp M Paprottka; Cinzia Pettinato; Macarena Rodríguez-Fraile; Riad Salem; Bruno Sangro; Lidia Strigari; Daniel Y Sze; Berlinda J de Wit van der Veen; Patrick Flamen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-12       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.